Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States.
Profile & Fundamentals
Beam Therapeutics: Company identity, ownership, reported financial performance, balance sheets, and corporate actions.
Profile & Fundamentals
Beam Therapeutics Profile & Fundamentals
Examine company identity, ownership, reported performance, valuation, balance-sheet resilience, dividends, buybacks, and material corporate events.
Explore this pageJump to a Profile & Fundamentals section
Explore this research
Profile & Fundamentals contents
Jump directly to any section
Company and Market Context
Company Profile & Ownership
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs. In addition, it develops BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE. The company has research collaboration agreement with Pfizer Inc., focusing on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Verve Therapeutics, Inc., for cardiovascular disease treatments; and Orbital Therapeutics to design RNA for the prevention, treatment, or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
Company profile record
Beam Therapeutics Inc
Common Stock · Health Care · Biotechnology
Company
- Company / asset
- Beam Therapeutics Inc
- Security type
- Common Stock
- Sector
- Health Care
- Industry
- Biotechnology
- HQ
- 🇺🇸 United States
- Head office
- 238 Main Street, Cambridge, MA, United States, 02142
Leadership & scale
- Chief executive
- Mr. John M. Evans M.B.A.
- CEO year born
- 1978
- Full-time employees
- 540
- Fiscal year end
- December
- IPO date
- 2020-02-06
Fundamentals snapshot
- Market Cap
- USD 2.6B
- P/E
- --
- Revenue (Q2 26)
- USD 490.0K
- Profit (Q2 26)
- USD -122.7M
- Dividend Yield
- --
- Revenue (FY 25)
- USD 139.7M
- Shares in public float
- 88.3M
- Insider ownership
- 1.25%
Reporting & identifiers
- Symbol
- BEAM.NASDAQ
- Listing
- 🇺🇸 United States | Dividend Tax: 30%
- Ticker Currency
- USD
- Income Statement Currency
- USD
- Balance Sheet Currency
- USD
- Cash Flow Currency
- USD
- EPS Currency
- USD
- Contract Type
- SPOT
- ISIN
- US07373V1052
- Asset ID
- equity_0a14ece2-c1cd-56c7-aa99-a17ab5832e4f
Ownership
Shares Outstanding
Latest: 104.3M | Max: 104.9M | Min: 30.7M
Latest reported ownership snapshot
As of Oct 1, 2026Float Shares
84.67%
88.3M latest reported shares
Insider Ownership
1.25%
Latest reported insider stake
Short Float
0.39%
Latest reported short interest / float
Top Holders
Source tablesView ownership tables
Shares Outstanding
Annual reported shares outstanding; up to 10 reporting dates.
Scroll the table to see every column.
| Reporting date | Shares outstanding |
|---|---|
| 2018-01-01 | 35,137,600 |
| 2019-01-01 | 30,725,100 |
| 2020-01-01 | 60,210,100 |
| 2021-01-01 | 67,988,700 |
| 2022-01-01 | 70,777,500 |
| 2023-01-01 | 82,702,300 |
| 2024-01-01 | 82,824,200 |
| 2025-01-01 | 104,927,000 |
| 2026-01-01 | 104,326,700 |
Top Holders
Available reported ownership records.
Scroll the table to see every column.
| Holder | Shares | Ownership | Reported date |
|---|---|---|---|
| FMR Inc | 12,452,199 | 12.06% | 2026-03-31 |
| ARK Investment Management LLC | 12,133,433 | 11.75% | 2026-03-31 |
| Farallon Capital Management, L.L.C. | 10,134,696 | 9.81% | 2026-03-31 |
| BlackRock Inc | 8,487,569 | 8.22% | 2026-03-31 |
| ARK Innovation ETF | 5,853,508 | 5.67% | 2026-08-31 |
| State Street Corp | 5,699,265 | 5.52% | 2026-03-31 |
| Vanguard Portfolio Management, LLC | 4,570,797 | 4.43% | 2026-03-31 |
| ARCH VENTURE CORP | 4,540,132 | 4.4% | 2026-06-30 |
| Vanguard Capital Management, LLC | 4,377,374 | 4.24% | 2026-03-31 |
| State Street® SPDR® S&P® Biotech ETF | 3,553,962 | 3.44% | 2026-08-31 |
| Fidelity Growth Company Fund | 3,457,347 | 3.35% | 2026-07-31 |
| Amova Asset Management Americas, Inc | 3,455,043 | 3.35% | 2026-06-30 |
| Sumitomo Mitsui Trust Group Inc | 3,455,043 | 3.35% | 2026-06-30 |
| Vanguard MStar Total Stk Mkt Idx Invest | 3,282,204 | 3.18% | 2026-08-31 |
| Kynam Capital Management, LP | 2,840,792 | 2.75% | 2026-06-30 |
Earnings, Profitability & Valuation
Earnings, Profitability & Valuation
Earnings & Revenue
Earnings and Revenue Trajectory
AI Review
The company's headline revenues resemble an irregular burst pattern rather than a traditional business. While trailing twelve-month revenues reached $156 million due to intermittent partnership payments, quarterly receipts plunged to just $490 thousand in mid-2026. This extreme swing occurs because the business has no approved commercial drugs on the market yet, relying entirely on sporadic upfront licensing checks from large pharmaceutical partners. Behind the headline numbers sits a steady clinical engine consuming cash. Trailing operating losses of $378 million and free cash flow burn of $373 million reflect intense development expenditures across parallel human trials. Until proprietary therapies secure regulatory approval and generate commercial sales, reported earnings will remain deeply negative, making clinical milestones far more informative than quarterly accounting profits.
The company's headline revenues resemble an irregular burst pattern rather than a traditional business. While trailing twelve-month revenues reached $156 million due to intermittent partnership payments, quarterly receipts plunged to just $490 thousand in mid-2026. This extreme swing occurs because the business has no approved commercial drugs on the market yet, relying entirely on sporadic upfront licensing checks from large pharmaceutical partners. Behind the headline numbers sits a steady clinical engine consuming cash. Trailing operating losses of $378 million and free cash flow burn of $373 million reflect intense development expenditures across parallel human trials. Until proprietary therapies secure regulatory approval and generate commercial sales, reported earnings will remain deeply negative, making clinical milestones far more informative than quarterly accounting profits.
Revenue, Net Income, and Free Cash Flow
Latest: USD 139.7M | Max: USD 377.7M | Min: USD -376.7M
Valuation
P/E Ratio (TTM)iPublished valuation snapshots use the earnings basis recorded with each observation. Source tables retain that basis.
Latest: --
No history available.
Profitability & Margins
Margins and Operating Efficiency
AI Review
Examining traditional profit margins today reveals the distorted economics of pre-commercial biotechnology. Operating margins registered at negative 275% in fiscal 2025, swinging alongside lumpy collaboration revenue recognition. While gross margins can appear deceptively high at 84% during milestone quarters, ongoing operational overhead ensures substantial net losses while treatments remain in clinical testing. These negative margins represent intentional developmental investments rather than flawed long-term unit economics. Once systemic in vivo therapies clear regulatory approvals, the underlying economics of precision genetic medicines are expected to yield commercial gross margins exceeding 80%. As commercial product sales scale, high unit profitability should rapidly absorb fixed platform overhead, driving significant operating margin expansion.
Examining traditional profit margins today reveals the distorted economics of pre-commercial biotechnology. Operating margins registered at negative 275% in fiscal 2025, swinging alongside lumpy collaboration revenue recognition. While gross margins can appear deceptively high at 84% during milestone quarters, ongoing operational overhead ensures substantial net losses while treatments remain in clinical testing. These negative margins represent intentional developmental investments rather than flawed long-term unit economics. Once systemic in vivo therapies clear regulatory approvals, the underlying economics of precision genetic medicines are expected to yield commercial gross margins exceeding 80%. As commercial product sales scale, high unit profitability should rapidly absorb fixed platform overhead, driving significant operating margin expansion.
Profitability Margins
Latest: 84.0% | Max: 100.0% | Min: <-100.0%
Latest Profitability Ratios as of 2025-12-31
Gross Margin
84.0%
Gross profit / revenue
Operating Margin
-274.6%
Operating income / revenue
Net Margin
-57.2%
Net income / revenue
FCF Margin
-257.7%
Free cash flow / revenue
Source tablesView earnings, profitability & valuation tables
Revenue, Net Income, and Free Cash Flow
Annual reported results, using the source statement's recorded USD conversion. Up to 10 reporting periods; missing values are not estimated.
Scroll the table to see every column.
| Period end | Revenue (USD) | Net income (USD) | Free cash flow (USD) |
|---|---|---|---|
| 2017-12-31 | Not reported | -8,729,454 | -3,053,000 |
| 2018-12-31 | 0 | -115,257,000 | -33,422,000 |
| 2019-12-31 | 18,000 | -78,326,000 | -84,521,000 |
| 2020-12-31 | 24,000 | -194,592,000 | -112,098,000 |
| 2021-12-31 | 51,844,000 | -370,638,000 | -113,079,000 |
| 2022-12-31 | 60,920,000 | -289,088,000 | -26,424,000 |
| 2023-12-31 | 377,709,000 | -132,527,000 | -182,927,000 |
| 2024-12-31 | 63,518,000 | -376,742,000 | -356,192,000 |
| 2025-12-31 | 139,743,000 | -79,992,000 | -360,048,000 |
Published P/E Ratio
Published valuation snapshots retain each observation's earnings basis.
No reported records are available in this preview.
Profitability Margins
Matching annual reporting dates. Values are percentages.
Scroll the table to see every column.
| Period end | Gross margin (%) | Operating margin (%) | Net margin (%) | Free cash flow margin (%) |
|---|---|---|---|---|
| 2017-12-31 | Not reported | Not reported | Not reported | Not reported |
| 2018-12-31 | Not reported | Not reported | Not reported | Not reported |
| 2019-12-31 | -303,338.89 | -417,522.22 | -435,144.44 | -469,561.11 |
| 2020-12-31 | -429,812.5 | -553,166.66 | -810,800 | -467,075 |
| 2021-12-31 | -347.75 | -757.01 | -714.91 | -218.11 |
| 2022-12-31 | -411.48 | -555.61 | -474.54 | -43.37 |
| 2023-12-31 | 100 | -46.73 | -35.09 | -48.43 |
| 2024-12-31 | -478.67 | -654.25 | -593.13 | -560.77 |
| 2025-12-31 | 84.05 | -274.57 | -57.24 | -257.65 |
Public data excerpt created by iPulse AI and published by Future Edge Group FZE. Source: eodhd. Snapshot retrieved 2026-10-01.
Use is subject to the iPulse AI Terms of Service and applicable source rights. Missing inputs are not estimated. Full access includes the remaining records, research and interactive tools.
Complete Research Workspace
Unlock the complete Profile & Fundamentals
Sign in to verify your access, or upgrade to the Base plan to open the complete profile & fundamentals and available source data.